Organogenesis Q3 revenue $113.8M (+13% YoY), net income $12.6M, FY2021 guidance $458-470M

Organogenesis Holdings Inc.

2021-Q3 EPS reported $0.32 revenue$339,501,000

Net revenue $113.8M (+13% YoY); Advanced Wound Care $107.3M (+19%), Surgical & Sports Medicine $6.4M (-41%).
Net income $12.6M ($0.09 diluted EPS) vs $20.8M ($0.19) in Q3 2020; adj. EBITDA $21.7M (19% margin).
FY2021 guidance: net revenue $458-470M (35-39% growth); Advanced Wound Care $425-434M, PuraPly $196-204M.
Cash $102.7M, debt $83.2M as of Sept 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.